Spyre Therapeutics grants stock options to four new employees as hiring incentives.

Spyre Therapeutics approved stock options for four non-executive employees as inducement awards to attract talent. The options cover 20,800 shares at an exercise price of $69.42, with a 10-year term and vesting over four years. This move supports Spyre's growth as it advances its pipeline of long-acting antibodies for inflammatory and rheumatic diseases. The grants align with Nasdaq rules and aim to retain key staff during clinical development phases.